Valneva (VALN) News Today

Valneva SE (NASDAQ: VALN) shares increased as investors focused on progress toward regulatory review of its Lyme disease vaccine candidate, although the company’s weak quarterly results remain a risk.

• Positive Sentiment: The European Medicines Agency validated Pfizer and Valneva’s marketing authorization application for their six-valent Lyme disease vaccine candidate, PF-07307405. The validation allows the EMA to begin its formal assessment, a significant step toward potential approval and commercialization. The vaccine is being developed in partnership with Pfizer, with regulatory decisions potentially targeted within the next year. Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: Investor attention is increasing around the potential Lyme vaccine market. Reports said the European Union will study the candidate, which could address an unmet need as Lyme disease cases rise and no broadly available human vaccine is currently marketed. EU to study potential vaccine for Lyme disease: companies
• Neutral Sentiment: TD Cowen initiated research coverage on Valneva. New analyst coverage may improve visibility, but the article did not provide a rating or price target that would establish a clear trading signal. Valneva Research Coverage Started at TD Cowen
• Negative Sentiment: Valneva’s second-quarter earnings missed expectations: the company reported a loss of $0.40 per share versus a consensus loss of $0.23, while revenue of $39.37 million fell short of the $43.15 million estimate. The company continues to report substantial losses, reflected in its negative net margin and return on equity. Valneva Earnings Results
• Neutral Sentiment: Management reaffirmed its 2026 financial outlook while emphasizing a strategic focus on commercial execution and the Lyme vaccine program. The guidance provides some visibility, but profitability and the timing of potential Lyme vaccine revenue remain uncertain. Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates